Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
Arcutis Biotherapeutics(ARQT.US) Officer Sells US$68,581.99 in Common Stock
$Arcutis Biotherapeutics(ARQT.US)$ Officer Edwards Larry Todd sold 7,640 shares of common stock on May 17, 2024 at an average price of $8.9767 for a total value of $68,581.99.Source: Announcement What
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 101.09%: Here's Is How to Trade
Express News | Arcutis Biotherapeutics Inc : Guggenheim Raises Target Price to $27 From $26
Arcutis Biotherapeutics Is Maintained at Buy by Needham
Arcutis Biotherapeutics Is Maintained at Buy by Needham
Express News | Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $18
NEXTracker Posts Upbeat Earnings, Joins Monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday.Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wednesday's session after the company reported better-than
Express News | Arcutis Biotherapeutics Shares up 13.5% After Higher Q1 Revenue
OPEN, BCRX and AWIN Among Pre-market Gainers
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday
Health care stocks rose pre-bell Wednesday, with the Health Care Select Sector SPDR Fund (XLV) recently 0.3% higher and the iShares Biotechnology ETF (IBB) up 0.6%. Arcutis Biotherapeutics (ARQT) rall
Sector Update: Health Care
Health care stocks were mixed pre-bell Wednesday with the Health Care Select Sector SPDR Fund (XLV) recently inactive and the iShares Biotechnology ETF (IBB) up 0.6%. Arcutis Biotherapeutics (ARQT) ra
Express News | Market-Moving News for May 15th
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.Arcutis Biotherapeutics
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersSINTX Techs (NASDAQ:SINT) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 d
Arcutis Biotherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 81.82% Mizuho $17 → $18 Maintains Buy 04/12/2024 61.62% Needham → $16 Reiterates Buy → Buy 02/2
Upgraded Buy Rating and Price Target for Arcutis Biotherapeutics Amid Zoryve's Robust Sales Performance
Express News | Arcutis Biotherapeutics Inc : Mizuho Raises Target Price to $18 From $17
Earnings Call Summary | Arcutis Biotherapeutics(ARQT.US) Q1 2024 Earnings Conference
The following is a summary of the Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript:Financial Performance:Arcutis reported Q1 2024 net revenues of $21.6 million, a 59% increase fro
Express News | Arcutis Biotherapeutics Shares Jump 24.4% Premarket After Higher Q1 Revenue
Investor Optimism: Arcutis (ARQT) Sees Stock Rise After Market Close
Tuesday's market closing saw Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) announce its financial results, and the company's stock price spiked significantly as a consequence. ARQT's shares increased 22.88% to $9.99 in the after-market trading, extending its regular session gain of 1.75% that ended at $8.13. Outstanding Growth Propelled By ZORYVE's Release With the successful introduction of ...